NFlection Therapeutics Seeking Adult Patients for Investigational Study on Cutaneous Neurofibromas (cNFs)

Author: NFlection Therapeutics
Published On: 10/12/2022

NFlection Therapeutics is currently recruiting adult patients for an investigational study of NFX-179 Topical Gel for reducing the appearance of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). NFX-179 is a topical, first-in-class, “soft” MEK inhibitor that is currently being evaluated in Phase 2 clinical trials. 

Volunteers, aged 18 years and older, are wanted for a clinical research study using an investigational topical medication. Patients must have a clinical diagnosis of NF1 and must have 10 or more cutaneous neurofibromas on their skin, including 1-2 on their face. During this study, all participants are seen by a board-certified physician. There is no cost for study-related evaluations and qualified participants will be reimbursed for time and travel. 

To learn more about this clinical trial and to be connected to available clinic sites, visit


Anyone considering participating in a clinical trial should discuss the matter with his or her physician. If you or a loved one is interested in participating in NF research, please read our clinical trials brochure to learn more about the clinical trial process and what that entails. 

Want to view archived newsletters? Click Here!


Sign up to receive the latest neurofibromatosis news and information in your inbox!



Have a story you'd like to share with the NF community? Click Here!